Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Rapamycin and CCI-779].

J Alexandre1, E Raymond, J P Armand

  • 1Département de médecine, Institut Gustave-Roussy, 94805 Villejuif Cedex.

Bulletin Du Cancer
|November 26, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Pressure ulcer following compression otoplasty garment: A rare but severe case report].

Annales de chirurgie plastique et esthetique·2026
Same author

[Fasciitis-like primary breast pyoderma gangrenosum: A rare case report].

Annales de chirurgie plastique et esthetique·2026
Same author

Declining research interest among oncology residents: insights into the academic career from a nationwide longitudinal study in France.

ESMO open·2026
Same author

Unravelling the role of environmentally realistic concentrations of titanium dioxide nanoparticles in altering gametogenesis and gonadal health of female Pacific oysters (Magallana gigas): a histopathological approach.

Aquatic toxicology (Amsterdam, Netherlands)·2025
Same author

Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe study.

ESMO open·2025
Same author

Search for Highly Ionizing Particles in pp Collisions during LHC Run 2 Using the Full MoEDAL Detector.

Physical review letters·2025
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Rapamycin, an immunosuppressant, shows antiproliferative effects against tumors. Its analog, CCI-779, demonstrates antitumor activity with reduced immunosuppression in preclinical models.

Area of Science:

  • Pharmacology
  • Oncology
  • Immunology

Context:

  • Rapamycin (sirolimus) is a macrolide with immunosuppressive and antiproliferative properties.
  • It targets the mechanistic target of rapamycin (mTOR) kinase, crucial for protein synthesis.
  • Clinical trials of oral rapamycin for immunosuppression showed manageable toxicity.

Purpose:

  • To evaluate the antitumor potential of rapamycin and its analogs.
  • To investigate the efficacy and safety of intravenous rapamycin formulations.
  • To explore the relationship between immunosuppressive and antitumor activities.

Summary:

  • Rapamycin exhibits antiproliferative activity in human tumor cell lines and xenografts.
  • Oral rapamycin as an immunosuppressant had limited dose-related toxicity.

Related Experiment Videos

  • Intravenous analog CCI-779 showed antitumor activity in murine models with minimal immunosuppression.

    • Impact:

    • Rapamycin analogs like CCI-779 represent a promising therapeutic strategy for cancer treatment.
    • Understanding mTOR inhibition offers new avenues for targeted cancer therapies.
    • Further clinical investigation of CCI-779 is warranted for its antitumor potential.